{"id":908773,"date":"2025-11-12T10:15:05","date_gmt":"2025-11-12T15:15:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/"},"modified":"2025-11-12T10:15:05","modified_gmt":"2025-11-12T15:15:05","slug":"lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/","title":{"rendered":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Nov.  12, 2025  (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals, Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer.<\/p>\n<p>Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands.<\/p>\n<p>\u201cWe are very pleased to welcome Kaya to LB Pharmaceuticals,\u201d said Heather Turner, Chief Executive Officer. \u201cHer deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya\u2019s proven ability to translate science into patient and market impact will be key to maximizing the potential of LB-102 and driving long-term value creation.\u201d<\/p>\n<p>Before joining LB Pharmaceuticals, Ms. Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics, a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases. Previously, she was Head of Commercial at Cerevel Therapeutics, which was acquired by AbbVie in 2024, and General Manager, Neuroscience at Lundbeck U.S., where she oversaw the U.S. launches of REXULTI<sup>\u00ae<\/sup> and TRINTELLIX<sup>\u00ae<\/sup>, and the bipolar indication for ABILIFY MAINTENA<sup>\u00ae<\/sup>, achieving blockbuster sales across the neuropsychiatry portfolio.<\/p>\n<p>\u201cIt\u2019s an exciting time to join LB Pharmaceuticals as we prepare to advance a differentiated therapy for schizophrenia and bipolar depression, with potential to benefit patients across a broader range of neuropsychiatric disorders,\u201d said Ms. Pai Panandiker. \u201cLB-102 represents meaningful innovation in an area of high unmet need, and I look forward to working with the LB team to bring this important treatment to patients.\u201d<\/p>\n<p>Ms. Pai Panandiker holds a Master\u2019s degree in Public Policy from the University of Chicago and a Bachelor of Arts from the University of Wisconsin\u2013Madison.<\/p>\n<p>\n        <strong>About LB-102<\/strong>\n      <\/p>\n<p align=\"justify\">LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer\u2019s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.<\/p>\n<p>\n        <strong>About LB Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpositioned,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102 and continuing advancement of LB-102 and the Company\u2019s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company\u2019s limited operating history and historical losses; the Company\u2019s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company\u2019s dependence on the success of its lead product candidate, LB-102; the Company\u2019s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company\u2019s lead product candidate, LB-102; any undesirable side effects or other properties of the Company\u2019s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company\u2019s ability to obtain, maintain and protect its intellectual property; and the Company\u2019s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.<\/p>\n<p align=\"justify\">These and other risks are described more fully in the section titled \u201cRisk Factors\u201d in the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <u>Media<\/u>:\u00a0<br \/>Michael Tattory<br \/>LifeSci Communications <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hiVgAzes1JNCL5aCzzz17bD-Ol9CYos1tqx9sQnJKR8ueWejCaL2vVEBe-M7Kp9PZvy-mFewOf9_c48whtTzekvnDk3wixGV9UWoHJpWfcHRHqhqbg_YDTuUJFGwlujf\" rel=\"nofollow\" target=\"_blank\">Mtattory@lifescicomms.com<\/a><\/p>\n<p>\n        <br \/>\n        <u>Investor Relations<\/u>:\u00a0<br \/>Joyce Allaire\u00a0<br \/>LifeSci Advisors\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RE7LNDPYsCDOGNVrsXQSN2kgHpoKXJ22gcFrXmknBxKRT8MYib7WQa_94YuT5sk5a-pFtbX2WUwFtVnAShQxzZN12iWiKh6SPgyE1AWlAa0AYD8K_ZZXNsvuuE2t8FXP\" rel=\"nofollow\" target=\"_blank\">JAllaire@LifeSciAdvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDIyMzI4YzQtMTA0My00MzE5LWE4MjgtMzgzNDQ2OTBmZDdjLTUwMDEzMDE5NS0yMDI1LTExLTEyLWVu\/tiny\/LB-Pharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals, Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. \u201cWe are very pleased to welcome Kaya to LB Pharmaceuticals,\u201d said Heather Turner, Chief Executive Officer. \u201cHer deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya\u2019s proven ability to translate &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908773","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals, Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. \u201cWe are very pleased to welcome Kaya to LB Pharmaceuticals,\u201d said Heather Turner, Chief Executive Officer. \u201cHer deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya\u2019s proven ability to translate &hellip; Continue reading &quot;LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T15:15:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer\",\"datePublished\":\"2025-11-12T15:15:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/\"},\"wordCount\":931,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/\",\"name\":\"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\",\"datePublished\":\"2025-11-12T15:15:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk","og_description":"NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; LB Pharmaceuticals, Inc (\u201cLB Pharmaceuticals\u201d or the \u201cCompany\u201d) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. \u201cWe are very pleased to welcome Kaya to LB Pharmaceuticals,\u201d said Heather Turner, Chief Executive Officer. \u201cHer deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya\u2019s proven ability to translate &hellip; Continue reading \"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T15:15:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer","datePublished":"2025-11-12T15:15:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/"},"wordCount":931,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/","name":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==","datePublished":"2025-11-12T15:15:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Mjc3NiM3MjU1NjI4IzUwMDEzMDE5NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lb-pharmaceuticals-appoints-kaya-pai-panandiker-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908773"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908773\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}